The significant long-term growth of Regeneron Pharmaceuticals, as highlighted by the 22.65% average annual return over 20 years, underscores the company's strong performance and potential appeal to investors. This historical performance, especially with a current market cap of $99.62 billion, suggests a positive outlook that could continue to attract investor interest in the short term.